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A B S T R A C T
Background: Percutaneous balloon mitral valvotomy (PBMV) is generally considered as a contraindica-
tion in patients with mitral stenosis (MS) associated with moderate to severe mitral regurgitation (MR).
We sought to compare the safety and efﬁcacy of PBMV in patients with severe MS and with moderate MR
with those with less than moderate or no MR.
Materials and methods: Symptomatic patients of MS with mitral valve area 1.5 cm2 were screened into
two groups: Group I with moderate MR and Group II with less than moderate or no MR. Clinical and
echocardiographic assessments were done at 24 h, 1 month, and 6 months post-procedure. A treadmill
testing was done prior to PBMV and at 6 months.
Primary safety outcome was a composite of cardiovascular death and development of severe MR with
or without requirement for mitral valve replacement at 30 days of procedure. Efﬁcacy of the procedure
was measured as improvement in functional class, treadmill time, and mitral valve area (MVA) at
6 months.
Results: Seventeen patients with moderate MR and 208 patients with less than moderate MR underwent
PBMV. Primary outcome showed no signiﬁcant difference [2 (11.7%) in Group I vs. 8 (3.85%) in Group
II, p = 0.36]; occurrence of severe MR was higher in Group I [RR = 4.87, 95% C.I. = 1.42–16.69]. In Group
I patients, improvement in treadmill time was seen in 12 (70.59%), functional class in 13 (76.47%), and
MVA in all patients.
Conclusion: In patients having severe MS associated with moderate MR, PBMV may be a safe option and
provides sustained symptomatic beneﬁt.
 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Rheumatic heart disease (RHD) remains a major public health
problem in India. A survey of secondary care hospitals shows that
nearly 30% of cardiac cases are related to RHD.1 As per WHO
estimates, nearly 0.133 million deaths annually were attributable
to RHD in the Southeast Asia region.2 Severe mitral stenosis (MS) is
the major cause for hospital admissions and limitations in the
functional capacity of patients with RHD. Percutaneous balloon
mitral valvotomy (PBMV) is a safe and effective treatment for
symptomatic severe MS [mitral valve area (MVA) <1.5 cm2] with* Corresponding author at: Peringadan House, P.O. Chazhur, Thrissur, Kerala
680571, India. Tel.: +91 9633413456.
E-mail address: drpgnithin@gmail.com (N.G. Peringadan).
http://dx.doi.org/10.1016/j.ihj.2016.04.025
0019-4832/ 2016 Cardiological Society of India. Published by Elsevier B.V. This is an
licenses/by-nc-nd/4.0/).favorable valve morphology. Presence of moderate mitral regurgi-
tation (MR) is considered a contraindication to PBMV.3 It is
estimated that around 40% of all patients with RHD have combined
MS and MR.4 A signiﬁcant proportion of patients with symptomatic
severe MS have associated moderate MR. These patients are
referred for mitral valve replacement (MVR), even though they
otherwise have no indication for MVR, exposing them to surgical
risk and long-term risks of anticoagulation and infective endocar-
ditis. Preserving the native valve with relief of obstruction is an
attractive option for this subset of patients.
2. Aims and objectives
We hypothesized that symptomatic patients with severe MS
and associated moderate MR can be safely subjected to PBMV open access article under the CC BY-NC-ND license (http://creativecommons.org/
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signiﬁcant symptom alleviation.
The primary aim was to examine whether the composite of
cardiovascular death and severe MR with or without requirement
of MVR in patients undergoing PBMV for severe MS was
signiﬁcantly different in those having associated moderate MR
as compared to those with mild or no MR. The secondary aim was
to see whether patients undergoing PBMV for MS and associated
moderate MR had improvement in their functional status and MVA
after the procedure and had sustained symptomatic beneﬁt at
6 months.
3. Patients and methods
Our study was a prospective cohort study approved by the
Institutional Ethics Committee. Consecutive patients with symp-
tomatic severe MS [2D-MVA < 1.5 cm2] were screened. These
patients were evaluated clinically by transthoracic echocardiogra-
phy [TTE] and transesophageal echocardiography [TEE] for the
presence and severity of associated MR and suitability for PBMV.
Patients with severe MR, valves with unsuitable morphology
(patients with Wilkins score >12 and those with heavy mitral valve
calciﬁcation as judged by echocardiography and/or ﬂuoroscopy), left
atrial clot, requiring cardiac surgery for other indications, and those
who refused to give consent were excluded. We divided patients
with suitable morphology for PBMV into two groups depending on
the severity of MR: Group I included patients with moderate MR and
Group II included patients with less than moderate MR or no MR.
Patients with moderate MR were given the option of either MVR or a
high-risk PBMV under MVR backup. Patients opting for PBMV were
enrolled in the study after informed consent.
We performed TTE and TEE reevaluations prior to PBMV in all
patients. The following parameters were reassessed: 2D-MVA,
mitral diastolic gradients, extent of mitral valve calcium, extent of
subvalvular pathology, and MR jet characteristics – width of vena
contracta (VC), effective regurgitant oriﬁce area (EROA), regur-
gitant volume (R Vol.), and regurgitant fraction (RF). A treadmill
testing (TMT) using Bruce protocol was done prior to PBMV for
functional assessment of the patient.
We performed coronary angiogram just prior to PBMV. Left
ventricular angiogram was done just prior to and immediately
after PBMV to assess the degree of MR. Pulmonary artery (PA)
pressures and pulmonary capillary wedge pressures were also
taken prior to the procedure.
We did PBMV following standard technique.5 Pressure gradient
across the mitral valve was measured by simultaneous pressure
recordings in left atrium and left ventricle. Valvotomy was done
using single balloon technique using PBMV balloon (PBMV balloon
catheter set, Shenzhen Shineyard Medical Device Co Ltd.,
Shenzhen, China). Sizing of the balloon was done using Hung’s
formula6 [patient’s height in cm is rounded to nearest zero and
divided by 10, and 10 is added to the ratio to yield the reference
size in mm]. Initial dilatation was done using a size 1 mm less than
the calculated balloon size. The need for subsequent dilatation was
assessed by the operator on the basis of echocardiography and
clinical examination. The reason for repeat dilatation and size of
balloon was noted. Pulmonary artery pressure was measured soon
after the procedure in addition to valve gradient.
Clinical and echocardiographic assessment was done within
24 h, at 1 month, and at 6 months post-procedure in Group I.
Symptom status (based on New York Heart Association (NYHA)
functional class) was noted and TMT was done at 6 months post-
procedure for objective assessment of functional status. The
primary outcome measured was a composite of cardiovascular
death within 30 days of procedure, MVR within 30 days for severe
MR intractable to medical management, and development ofsevere MR [not undergoing urgent MVR]. The secondary outcome
measured was the improvement in the treadmill time (in min),
NYHA functional class, and in 2D-MVA at 6 months.
3.1. Deﬁnitions
We deﬁned severe MS as MVA <1.5 cm2. Moderate MR
described MR jet with any one of the following features: VC
0.3–0.69 cm, EROA 0.20–0.39 cm2, R Vol. 30–59 > 0.70 cm, EROA
>0.40 cm2, R Vol. >60 ml/beat, and RF >50% constituted severe
MR. Satisfactory improvement in MVA was deﬁned as more than
50% of baseline value or valve area greater than 1.5 cm2.
3.2. Statistical analysis
We used IBM SPSS software (IBM SPSS Statistics for Windows,
Version 20.0. Armonk, NY: IBM Corp. released 2011) for the
statistical analysis. Baseline characteristics between the two
groups were compared using Pearson chi-square test for signiﬁ-
cance. The composite of primary end points was calculated and
compared between the two groups by Pearson chi-square test with
Yates’s correction for signiﬁcance. The relative risk for developing
severe MR was also calculated. Secondary end points were
measured in the group with preexisting moderate MR and
compared using Student’s paired t test. The average improvement
in the TMT time was noted. The average improvement in MVA of
each patient was calculated and improvement in NYHA functional
class noted. Also the degree of MR as assessed by the
echocardiographic parameters [VC, EROA, R Vol., and RF] was
compared between pre-BMV at 24 h after PBMV and at 6 months. A
p-value of <0.05 was taken to be signiﬁcant.
4. Results
4.1. Baseline characteristics
The study period was between February 2012 and May 2013.
Fig. 1 depicts the exclusions and the ﬁnal sample.
There were 17 patients in Group I and 208 in Group II. Both groups
were comparable with respect to baseline characteristics, as shown
in Table 1. The median Wilkins score of Group I was 7 (range 6–12).
4.2. Safety of PBMV in MS with moderate MR
All 17 patients in Group I underwent PBMV. The preprocedure
and immediate post-procedure MVA were 0.886 (0.16) and 1.7
(0.28), respectively. The Mean (SD) PA systolic pressure soon after
the procedure was 42.3 (12.5) mmHg. The primary outcomes at
1 month are as depicted in Table 2.
Overall, there were 2 instances of severe MR in Group I and 8 in
Group II. Those in Group I who developed severe MR had Wilkins
score of 12 and 11. There was one death at 30 days of PBMV, which
occurred in Group II. This patient developed acute severe MR due
to anterior mitral leaﬂet (AML) tear with severe hypotension and
arterial oxygen desaturation, and died while being shifted for an
emergency MVR. All patients who developed severe MR after BMV
were counseled and posted for urgent or elective MVR. Three
patients in Group II developed symptomatic severe MR, and
underwent emergency MVR. Two patients in Group I and four
patients of Group II who developed severe MR declined surgical
correction and were medically managed. None of them died during
the 30-day follow-up; one of these patients from Group I died after
3 months. The relative risk of developing severe MR was greater in
patients with preexisting moderate MR [RR = 4.87, 95% C.I. = 1.42–
16.69]. The composite of primary events was not statistically
Table 1
Baseline characteristics.
Parameter Group I [n = 17] Group II [n = 208] p value
Age, years, mean (SD) 46.2 (10.8) 41.0 (11.6) p = 0.076
Women (%) 88.2% 75% p = 0.498
NYHA class (%)
Class III 76.5 77.2 p = 0.521
Class IV 23.5 22.8
Pulmonary artery systolic pressure, mmHg, mean (SD) 47.7 (15.8) 42.5 (17.4) p = 0.345
Presence of atrial ﬁbrillation (%) 76% 71% p = 0.323
Mean mitral gradients by echo, mean (SD) 13.4 (2.3) 12.9 (2.5) p = 0.723
2-D MVA, cm2, mean (SD) 0.886 (0.16) 0.875 (0.18) p = 0.808
Site of calcium, n (%)
Nil 10 (58.8%) 147 (70.7%) p = 0.099
Unicommissural 2 (11.8%) 13 (6.2%)
Bicommissural 1 (5.9%) 10 (4.8%)
Leaﬂet 4 (23.5%) 38 (18.3%)
Subvalvular pathology [as n (%)]
Nil 0 43 (20.7%) p = 0.073
Mild 11 (64.7%) 106 (51%)
Moderate 5 (29.4%) 57 (27.4%)
Severe 1 (5.9%) 2 (1%)
Fig. 1. Flow chart showing selection of patients in Group I.
Table 2
Primary outcomes.
Group I [n = 17] Group II [n = 208] p value
CV death within 30 days 0 1 (0.48%) p = 0.1
MVR for severe MR within 30 days 0 3 (1.44%) p = 0.54
Severe MR who did not undergo MVR 2 (11.76%) 4 (1.92%) RR = 4.87 (95%
C.I. = 1.42–16.69)
Composite 2 (11.76%) 8 (3.85%) p = 0.36
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II – 8 (3.85%), p = 0.36].
4.3. Efﬁcacy of PBMV in MS with moderate MR
Five patients in Group I could not undergo TMT due to
musculoskeletal impairment. All other patients showed signiﬁcant
improvement in treadmill time after PBMV. Thirteen patients
(76.47%) showed improvement in their NYHA functional class. Out
of the 13 patients who were class III, 11 improved to class I and 2
patients with asthma remained class III. Out of the 4 patients who
were class IV, 2 developed severe MR and remained class IV; 1
patient improved to class III and one to class II. All patients hadsigniﬁcant improvement in their 2D-MVA with a percentage
change of 86.5% in the valve area (Table 3).
In patients with Group I, the degree of mitral regurgitation was
assessed via various echocardiographic criteria. There was a
signiﬁcant increase in moderate MR post-procedure in all patients,
as shown in Table 4. Only two patients had values in the range of
severe MR. There was no increase in values at 180 days compared
to the immediate post-procedure values.
5. Discussion
Our study compared the safety and efﬁcacy of performing
PBMV in patients with severe MS associated with moderate MR
Table 3
Secondary outcomes in Group I.
Parameter Pre-PBMV 6 months after PBMV Difference p value
Treadmill time, min, mean (SD) 3.1 (+0.66) 7.17 (+2.12) 4.07 (+1.61) p < 0.001, 95%
CI = 3.0–5.1
MVA, cm2, mean (SD) 0.89 (+0.16) 1.62 (+0.31) 0.73 (0.28) p < 0.05
PA systolic pressure, mmHg, mean (SD) 47.7 (15.8) 37.4 (13.2) 10.3 (4.99) p < 0.05
NYHA class
I 12
II 13 1
III 4 2
IV 2
Table 4
Evaluation of mitral regurgitation pre- and post-BMV.
MR parameters Pre-PBMV [mean (SE)] Post-PBMV [mean (SE)] After 6 months [mean (SE)] Signiﬁcance*
VC (cm) 0.376 (0.02) 0.567 (0.02) 0.557 (0.02) p1< 0.001
p2 = 0.248
EROA (cm2) 0.271 (0.01) 0.345 (0.01) 0.344 (0.01) p1< 0.001
p2 = 0.072
R Vol. (ml) 39.1 (1.0) 51.4 (1.69) 51.2 (1.78) p1< 0.001
p2 = 1.0
RF (%) 36.5 (0.83) 43.2 (0.67) 43 (0.70) p1< 0.001
p2 = 0.90
* p1 = signiﬁcance between pre-BMV and immediate post-BMV values; p2 = signiﬁcance between immediate post-BMV and values at 6 months.
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showed that the composite of CV death and occurrence of severe
MR, with or without requirement of urgent MVR at 1 month, was
not different from those with less than moderate MR. Signiﬁ-
cantly, higher proportion of patients developed severe MR in the
group with moderate MR. None of the patients in the group with
moderate MR had requirement for urgent MVR whereas
3 patients in the other group had the operation; the number
of patients with moderate MR was not sufﬁcient to make this
comparison though. The efﬁcacy of PBMV was assessed only in
the group with moderate MR and no comparison with the other
group was attempted. The efﬁcacy parameters of treadmill time,
functional class, and MVA showed improvement in this group at
6 months.
Development of severe MR is a well-recognized complication
after PBMV. Previous studies have shown the occurrence of severe
MR in patients with preexisting less than moderate or no MR to be
in the range of 1.4–9.4%.7 Many of these cases do not require early
MVR as the patients tolerate the complication reasonably well.
Among the patients who undergo PBMV, only 1.3–3.2% required
urgent MVR due to the development of severe MR.8,9 In some cases,
the MR severity has shown improvement over time.10,11 While in
our study the occurrence of severe MR was higher in the group
with preexisting moderate MR, none of the patients required MVR
during the 1-month follow-up. All these patients were considered
for elective MVR, and due to performance of PBMV in these
patients’, operation could be avoided or at least could be
postponed, thus obviating long-term anticoagulation and risk of
prosthetic valve endocarditis.
There are only very few studies comparing PBMV in patients
with MS and moderate MR with those with less than moderate MR.
Zhang et al. performed double balloon mitral valvotomy in
25 patients having symptomatic mitral stenosis with moderate
MR and showed that the possibility of developing moderate to
severe (3+) MR after balloon dilatation was greater in patients with
preexisting moderate MR as compared to 25 matched controls
having mild or no MR.12 In this study, 40% of patients had no
increase in MR and another 40% had an actual reduction in MR in
the moderate MR group, but 20% developed severe MR. In our
study, we found that all patients had an increase in MR but onlytwo (11%) developed severe MR. Lau et al. performed PBMV in
21 patients with moderate MR as compared to 83 patients without
moderate MR with Inoue balloon using serial dilation technique.13
The initial balloon size was much lower than that used in our
study; each dilation was followed by hemodynamic and clinical
evaluation and balloon size gradually uptitrated if required. The
ﬁnal balloon size was similar to that used in our study. With this
technique, there was an increase in MR but no severe MR was
reported in the study group. Even though the risk for developing
severe MR was greater in the patients with preexisting moderate
MR, no excess mortality in these patients was noted immediately
after the procedure, which is also reﬂected in our study. Patients
who did not develop severe MR after PBMV had signiﬁcant
symptomatic beneﬁt at 6-month follow-up post-procedure. Even
though patients have higher degrees of regurgitation than
previously, they tend to tolerate MR better with the improvement
in the MS, as evidenced by the higher NYHA functional class and
improved treadmill time. All the patients with moderate MR had
satisfactory improvement in MVA. Zhang et al. also showed that
the improvements in hemodynamics and increases in mitral valve
area can be equally achieved using balloon mitral valvotomy for
treatment of mitral stenosis in patients with or without moderate
MR.12 Similarly, Lau et al. showed that PBMV in patients with
moderate MR produced symptomatic beneﬁt in substantial
majority of patients (>90%) even at a mean follow-up of 19–20
months.13
It is worth noting that there was no patient with NYHA class II
symptoms in Group I. Most of the patients were far advanced in
symptoms as they constitute patients who either bear with
symptoms for paucity of ﬁnances or fear of procedures. The logistic
restrictions imposed by resources (the patients and the hospital)
also lead to deferring procedures until patients are severely
symptomatic. However, there was no difference between Groups I
and II in terms of symptomatic status.
The most important limitation of the study was the large
difference in the number of patients in the two groups, which made
the statistical comparison between the groups less reliable.
Although the baseline characteristics between the two groups
did not show statistically signiﬁcant difference, comparison would
have been better if matched controls were used. Suitability of valve
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system was used to identify the valve most suitable in this subset
of patients.
6. Conclusion
Our study is one of the few studies looking at the safety and
efﬁcacy of PBMV in patients with MS and moderate MR. It
compared the safety outcomes in MS patients with or without
moderate MR undergoing PBMV and showed that the composite
of CV death and development of MR is not signiﬁcantly higher in
patients with moderate MR. Sustained symptomatic beneﬁt [of
up to 6 months] and an improved functional status can be
achieved by PBMV in this subset of patients. Though MVR
currently remains the treatment of choice in this subgroup of
patients, our study shows that in suitably selected patients,
PBMV with a MVR backup may be offered safely. However, being
a small pilot study, it has some limitations and the conclusions
should be viewed with caution. Larger methodologically sound
studies enrolling more patients are needed to draw deﬁnitive
conclusions.
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